Pure Global
NCT05467254

Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML

To Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Zhejiang University·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
AML
Drug/Device/Intervention
CLL1+CD33 CAR-T
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Zhejiang University
Location
Hangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Aug 02, 2022
End date
Aug 02, 2025
Enrollment
20 participants
Primary outcome

Changes in cytokine level after CLL1+CD33 CAR-T infusion,The change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number in patients after infusion.

Summary

This is an open label, phase I study to assess the safety and efficacy of CLL1+CD33 CAR-T in
 patients with relapsed and refractory acute myeloid leukemia

ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05467254
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05467254 through Pure Global AI's free database. This Phase 1 trial is sponsored by Zhejiang University and is currently Not yet recruiting. The study focuses on AML. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.